PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has announced positive GLP toxicology study results for PYC-001, its novel drug candidate targeting Autosomal Dominant Optic Atrophy (ADOA), clearing the way for human clinical trials. The drug has shown effectiveness in both ‘retina in a dish’ models and animal studies, with no adverse events at the highest doses tested. With these successful outcomes, the company is set to submit a regulatory application to commence human trials, aiming for initial safety and efficacy data by 2025 and a New Drug Application in 2028.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
